Jeffrey Stein

Jeffrey Stein, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Cidara Therapeutics, Inc., Paratek Pharmaceuticals, Inc. and IDEAYA Biosciences, Inc. In total, 18 filings cover trades dated from 23 May 2016 to 2 March 2026.

The open-market side counts 6 purchases for €1.7M alongside 1 sale for €12k. Purchases outweigh sales by €1.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 6 share grants and 1 option exercise. So far in 2026, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €64k. Of 6 purchases, 1 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 2 March 2026, reports an open-market purchase of €1.4M in IDEAYA Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.